The development of COVID-19 treatment

被引：118
|
作者：
Yuan, Yongliang [1 ]
Jiao, Baihai [2 ]
Qu, Lili [3 ]
Yang, Duomeng [3 ]
Liu, Ruijuan [1 ]
机构：
[1] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[2] Univ Connecticut, Sch Med, Dept Med, Div Nephrol,Hlth Ctr, Farmington, CT USA
[3] Univ Connecticut, Sch Med, Dept Immunol, Hlth Ctr, Farmington, CT 06269 USA
来源：
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金：
中国国家自然科学基金;
关键词：
COVID-19; treatments; antiviral agents; neutralizing antibody therapy; Janus kinase inhibitors; JAK-STAT PATHWAY; OPEN-LABEL; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; RUXOLITINIB; STANDARD; MULTICENTER; FAVIPIRAVIR; TOFACITINIB; COMBINATION;
D O I：
10.3389/fimmu.2023.1125246
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest worldwide public health threat of this century. Recent studies have unraveled numerous mysteries of SARS-CoV-2 pathogenesis and thus largely improved the studies of COVID-19 vaccines and therapeutic strategies. However, important questions remain regarding its therapy. In this review, the recent research advances on COVID-19 mechanism are quickly summarized. We mainly discuss current therapy strategies for COVID-19, with an emphasis on antiviral agents, neutralizing antibody therapies, Janus kinase inhibitors, and steroids. When necessary, specific mechanisms and the history of therapy are present, and representative strategies are described in detail. Finally, we discuss key outstanding questions regarding future directions of the development of COVID-19 treatment.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19
    Florescu, Diana F.
    Kalil, Andre C.
    CURRENT OPINION IN CRITICAL CARE, 2021, 27 (05) : 493 - 496
  • [22] Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
    Naik, Rajashri R.
    Shakya, Ashok K.
    Aladwan, Safwan M.
    El-Tanani, Mohamed
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Treatments for COVID-19
    Andrews, Hayden S.
    Herman, Jonathan D.
    Gandhi, Rajesh T.
    ANNUAL REVIEW OF MEDICINE, 2024, 75 : 145 - 157
  • [24] Baricitinib: From Rheumatoid Arthritis to COVID-19
    Assadiasl, Sara
    Fatahi, Yousef
    Mosharmovahed, Banafsheh
    Mohebbi, Bahareh
    Nicknam, Mohammad Hossein
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (10): : 1274 - 1285
  • [25] Druggable targets and therapeutic development for COVID-19
    Duan, Xiaohua
    Lacko, Lauretta A.
    Chen, Shuibing
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [26] Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
    Qu, Na
    Hui, Zongguang
    Shen, Zhixin
    Kan, Chengxia
    Hou, Ningning
    Sun, Xiaodong
    Han, Fang
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Advances in the possible treatment of COVID-19: A review
    Chibber, Pankaj
    Haq, Syed Assim
    Ahmed, Irfan
    Andrabi, Nusrit Iqbal
    Singh, Gurdarshan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 883
  • [28] The role of immunomodulatory medications in the treatment of COVID-19
    Sattui, Sebastian E.
    Crow, Mary K.
    Navarro-Millan, Iris
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (05) : 431 - 445
  • [29] Stroke Treatment in the Era of COVID-19: a Review
    Simonetto, Marialaura
    Wechsler, Paul M.
    Merkler, Alexander E.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2022, 24 (04) : 155 - 171
  • [30] Investigational antiviral drugs for the treatment of COVID-19
    Vegivinti, C. T. R.
    Assi, M.
    Talwani, R.
    Koblizek, V
    Burke, K.
    Temesgen, Z.
    DRUGS OF THE FUTURE, 2021, 46 (09) : 697 - 710
12345